About GW Pharmaceuticals Plc

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

At the moment the company generates 13M USD in revenues.

On its last earning announcement, the company reported a loss of -10.56$ per share.

The book value per share is 23.28$

GW Pharmaceuticals Plc website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
13M 53.00% -289M -222.30% -295M -10.56 - - 28M 23.28 -232M -33M -265M